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Many common illnesses differentially affect men and women for unknown reasons.  The autoimmune 
diseases lupus and Sjögren’s syndrome affect nine times more women than men1, whereas 
schizophrenia affects men more frequently and severely2.  All three illnesses have their strongest 
common genetic associations in the Major Histocompatibility Complex (MHC) locus, an association 
that in lupus and Sjögren’s syndrome has long been thought to arise from alleles of the human 
leukocyte antigen (HLA) genes at that locus3-6.  Here we show that the complement component 4 (C4) 
genes, which are also in the MHC locus and were recently found to increase risk for schizophrenia7, 
generate 7-fold variation in risk for lupus (95% CI: 5.88-8.61; p < 10-117 in total) and 16-fold variation 
in risk for Sjögren’s syndrome (95% CI: 8.59-30.89; p < 10-23 in total) among individuals with 
common C4 genotypes, with C4A protecting more strongly than C4B in both illnesses.  The same 
alleles that increase risk for schizophrenia greatly reduced risk for lupus and Sjögren’s syndrome.  
In all three illnesses, C4 alleles acted more strongly in men than in women: common combinations of 
C4A and C4B generated 14-fold variation in risk for lupus, 31-fold variation in risk for Sjögren’s 
syndrome, and 1.7-fold variation in schizophrenia risk among men (vs. 6-fold, 15-fold, and 1.26-fold 
among women respectively).  At a protein level, both C4 and its effector C3 were present at greater 
levels in men than women in cerebrospinal fluid (p < 10-5 for both C4 and C3) and plasma8,9 among 
adults ages 20-50, corresponding to the ages of differential disease vulnerability.  Sex differences in 
complement protein levels may help explain the larger effects of C4 alleles in men, women’s greater 
risk of SLE and Sjögren’s, and men’s greater vulnerability in schizophrenia.  These results implicate 
the complement system as a source of sexual dimorphism in vulnerability to diverse illnesses.
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Systemic lupus erythematosus (SLE, or “lupus”) is a systemic autoimmune disease of unknown cause.  Risk 
of SLE is heritable (66%10), although SLE may have environmental triggers, as its onset often follows 
events that damage cells, such as infections and severe sunburns11.  Most SLE patients produce 
autoantibodies against nucleic acid complexes, including ribonucleoproteins and DNA12. 
 
In genetic studies, SLE associates most strongly with variation across the major histocompatibility complex 
(MHC) locus, which contains the human leukocyte antigen (HLA) genes3.  However, conclusive attribution 
of this association to specific genes and alleles has been difficult; the identities of the most likely genetic 
sources have been frequently revised as genetic studies have grown in size4,5.  In several other autoimmune 
diseases, including type 1 diabetes, celiac disease, and rheumatoid arthritis, strong effects of the MHC locus 
arise from HLA alleles that cause the peptide binding groove of HLA proteins to present a disease-critical 
autoantigen13,14.  In SLE, by contrast, genetic variants in the MHC locus (including SNPs and HLA alleles) 
associate broadly with the presence of diverse autoantibodies15.  
 
The complement component 4 (C4A and C4B) genes are also present in the MHC genomic region, between 
the class I and class II HLA genes.  Classical complement proteins help eliminate debris from dead and 
damaged cells, attenuating the visibility of diverse intracellular proteins to the adaptive immune system.  
C4A and C4B commonly vary in genomic copy number16 and encode complement proteins with distinct 
affinities for molecular targets17,18.  SLE frequently presents with hypocomplementemia that worsens during 
flares, possibly reflecting increased active consumption of complement19.  Rare cases of severe, early-onset 
SLE can involve complete deficiency of a complement component (C4, C2, or C1Q)20,21, and one of the 
strongest common-variant associations in SLE maps to ITGAM, which encodes a receptor for C3, the 
effector of C422.  Although total C4 gene copy number associates with SLE risk23,24, this association is 
thought to arise from linkage disequilibrium (LD) with alleles of nearby HLA genes25, which have been the 
focus of fine-mapping analyses3,4. 
 
The complex genetic variation at C4 – arising from many alleles with different numbers of C4A and C4B 
genes – has been challenging to analyze in large cohorts.  A recently feasible approach to this problem is 
based on imputation: people share long haplotypes with the same combinations of SNP and C4 alleles, such 
that C4A and C4B gene copy numbers can be imputed from SNP data7.  To analyze C4 in large cohorts, we 
developed a way to identify C4 alleles from whole-genome sequence (WGS) data (Extended Data Fig. 1a, 
b), then analyzed WGS data from 1,265 individuals (from the Genomic Psychiatry Cohort26,27) to create a 
large multi-ancestry panel of 2,530 reference haplotypes of MHC-region SNPs and C4 alleles (Extended 
Data Fig. 1c) – ten times more than in earlier work7.  We then analyzed SNP data from the largest SLE 
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genetic association study3 (ImmunoChip 6,748 SLE cases and 11,516 controls of European ancestry) 
(Extended Data Fig. 2a, b), imputing C4 alleles to estimate the SLE risk associated with common 
combinations of C4A and C4B gene copy numbers (Fig. 1a).   
 
Groups of research participants with the eleven most common combinations of C4A and C4B gene copy 
number exhibited 7-fold variation in their relative risk of SLE (Fig. 1a, Extended Data Fig. 2c).  The 
relationship between SLE risk and C4 gene copy number exhibited consistent, logical patterns across the 
11 genotype groups.  For each C4B copy number, greater C4A copy number associated with reduced SLE 
risk (Fig. 1a, Extended Data Fig. 2c).  For each C4A copy number, greater C4B copy number associated 
with more modestly reduced risk (Fig. 1a).  Logistic-regression analysis estimated that the protection 
afforded by each copy of C4A (OR: 0.54; 95% CI: [0.51, 0.57]) was equivalent to that of 2.3 copies of C4B 
(OR: 0.77; 95% CI: [0.71,0.82]).  We calculated an initial C4-derived risk score as 2.3 times the number of 
C4A genes, plus the number of C4B genes, in an individual’s genome.  Despite clear limitations of this risk 
score – it is imperfectly imputed from flanking SNP haplotypes (r2 = 0.77, Extended Data Table 1) and 
only approximates C4-derived risk by using a simple, linear model (to avoid over-fitting the genetic data) 
– SNPs across the MHC genomic region tended to associate with SLE in proportion to their level of LD 
with this risk score (Extended Data Fig. 3a).   
 
Combinations of many different C4 alleles generate the observed variation in C4A and C4B gene copy 
number; particular C4A and C4B gene copy numbers have also arisen recurrently on multiple SNP 
haplotypes7 (Extended Data Fig. 1c).  Analysis of SLE risk in relation to each of these C4 alleles and SNP 
haplotypes reinforced the conclusion that C4A contributes strong protection, and C4B more modest 
protection, from SLE, and that C4 genes (rather than nearby variants) are the principal drivers of this 
variation in risk levels (Fig. 1b).  
 
These results prompted us to consider whether other autoimmune disorders with similar patterns of genetic 
association at the MHC genomic region might also be driven in part by C4 variation.  Primary Sjögren’s 
syndrome (SjS) is a heritable (54%28) systemic autoimmune disorder of exocrine glands, characterized 
primarily by dry eyes and mouth with other systemic effects.  At a protein level, SjS is (like SLE) 
characterized by diverse autoantibodies, including antinuclear antibodies targeting ribonucleoproteins29, 
and hypocomplementemia30.  The largest source of common genetic risk for SjS lies in the MHC genomic 
locus31, with associations to the same haplotype(s) as in SLE6 and with heterogeneous HLA associations in 
different ancestries32.  We imputed C4 alleles into existing SNP data from a European-ancestry SjS case-
control cohort (673 cases and 1153 controls).  As in SLE, logistic-regression analyses found both C4A copy 
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number (OR: 0.41; 95% CI: [0.34, 0.49]) and C4B copy number (OR: 0.67; 95% CI: [0.53, 0.86]) to be 
protective against SjS.  The risk-equivalent ratio of C4B to C4A gene copies was similar in SjS and SLE 
(about 2.3 to 1); also, as with SLE, nearby SNPs associated with SjS in proportion to their LD with a C4-
derived risk score ((2.3)C4A+C4B ) (Extended Data Fig. 3b).  The distribution of SjS risk across the 
individual C4 alleles and haplotypes revealed a pattern that, as in SLE, supported greater protective effect 
from C4A than C4B, and little effect of flanking SNP haplotypes (Fig. 1b). 
 
The association of SLE and SjS with C4 gene copy number has long been attributed to the HLA-
DRB1*03:01 allele.  In European populations, DRB1*03:01 is in strong LD (r2 = 0.71) with the common 
C4-B(S) allele, which lacks any C4A gene and is the highest-risk C4 allele in our analysis (Fig. 1b); many 
MHC-region SNPs associated with SLE and SjS in proportion to their LD correlations with both C4 and 
DRB1*03:01 (Extended Data Fig. 4a, b).  Cohorts with other ancestries can have recombinant haplotypes 
that disambiguate the contributions of alleles that are in LD in Europeans.  Among African Americans, we 
found that common C4 alleles exhibited far less LD with HLA alleles; in particular, the LD between C4-
B(S) and DRB1*03:01 was low (r2 = 0.10) (Extended Data Table 2).  Thus, genetic data from an African 
American SLE cohort (1,494 cases, 5,908 controls) made it possible to distinguish between these potential 
genetic effects.  Joint association analysis of C4A, C4B, and DRB1*0301 implicated C4A (p < 10-14) and 
C4B (p < 10-5) but not DRB1*0301 (p = 0.29) (Extended Data Table 3).  Each C4 allele associated with 
effect sizes of similar magnitude on SLE risk in Europeans and African Americans (Fig. 2a).  An analysis 
specifically of combinations of C4-B(S) and DRB1*03:01 allele dosages in African Americans showed that 
C4-B(S) alleles consistently increased SLE risk regardless of DRB1*03:01 status, whereas DRB1*03:01 
had no consistent effect when controlling for C4-B(S) (Fig. 2b).  Although C4 alleles had less LD with 
nearby variants on African American than on European haplotypes, SNPs across the genomic region 
associated with SLE in proportion to LD correlations with C4 in African Americans as well (Extended 
Data Fig. 4c). 
 
Accounting for C4 alleles in jointly analyzing the SLE association data from African American and 
European ancestry cohorts also enabled the mapping of an additional, more-modest genetic effect 
independent of C4; this effect (tagged by rs2105898 and rs9271513) appeared to involve noncoding 
variation in the HLA class II XL9 region that associates most strongly with expression levels (rather than 
the coding sequence) of many HLA class II genes (Extended Data Figs. 3c, d, 4d-l, 5, and Supplementary 
Note 1).   
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Alleles at C4 that increase dosage of C4A (and to a more modest extent C4B) appear to protect strongly 
against SLE and SjS (Fig. 1a, b); by contrast, alleles that increase expression of C4A in the brain are more 
common among research participants with schizophrenia6.  These same illnesses exhibit striking, and 
opposite, sex differences: SLE and SjS are nine times more common among women of childbearing age 
than among men of a similar age1, whereas in schizophrenia, women exhibit less severe symptoms, more 
frequent remission of symptoms, lower relapse rates, and lower overall incidence2.  Though the vast 
majority of genetic associations in complex diseases are shared between men and women33, the SNPs that 
most strongly associate with SLE risk within the MHC region associate to larger potential effect sizes in 
men34.  Hence, we sought to evaluate the possibility that the effects of C4 alleles on risk in SLE, SjS, and 
schizophrenia might differ between men and women. 
 
Analysis indicated that the effects of C4 alleles were stronger in men.  When a sex-by-C4 interaction term 
was included in association analyses, this term was significant for both SLE (p = 0.002) and schizophrenia 
(p = 0.0024), with larger C4 effects in men for both disorders.  (Analysis of SjS had limited power due to 
the small number of men affected by SjS.)  For both SLE and schizophrenia, the individual C4 alleles 
consistently associated with stronger effects in men than women (Fig. 3a, b).  SNPs across the MHC 
genomic region exhibited sex-biased association to SLE, SjS, and schizophrenia to the extent of their LD 
with C4 (Extended Data Fig. 6a-c). 
 
The stronger effects of C4 alleles on male relative to female risk could arise from sex differences in C4 
RNA expression, C4 protein levels, or downstream responses to C4.  Analysis of RNA expression in human 
tissues, using data from GTEx35, identified no sex differences in C4 RNA expression in brain, blood, liver, 
or lymphoblastoid cells (a more-detailed description of this analysis can be found in Supplementary Note 
2).  We then analyzed C4 protein in cerebrospinal fluid (CSF) from two panels of adult research participants 
(n = 589 total) in whom we had also measured C4 gene copy number (by direct genotyping or imputation).  
CSF C4 protein levels correlated strongly with C4 gene copy number (p < 10-10, Extended Data Fig. 7a), 
so we normalized C4 protein measurements to the number of C4 gene copies.  CSF from adult men 
contained on average 27% more C4 protein per C4 gene copy than CSF from women (meta-analysis p = 
9.9 × 10-6, Fig. 3c).  C4 acts by activating the complement component 3 (C3) protein, promoting C3 
deposition onto targets in tissues.  CSF levels of C3 protein were also on average 42% higher among men 
than women (meta-analysis p = 7.5 × 10-7, Fig. 3d). 
 
The elevated concentrations of C3 and C4 proteins in CSF of men parallel earlier findings that, in plasma, 
C3 and C4 are also present at higher levels in men than women8,9.  The large sample size (n > 50,000) of 
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the plasma studies allows sex differences to be further analyzed as a function of age.  Both men and women 
undergo age-dependent elevation of C4 and C3 levels in plasma, but this occurs early in adulthood (age 
20–30) in men and closer to menopause (age 40–50) in women, with the result that male–female differences 
in complement protein levels are observed primarily during the reproductive years (ages 20–50)8,9.  We 
replicated these findings using measurements of C3 and gene copy number-corrected C4 protein in plasma 
from adults, finding (as in the earlier plasma studies8,9 and in CSF, Fig. 3c, d) that these differences are 
most pronounced during the reproductively active years of adulthood (ages 20-50) (Extended Data Fig. 
7b-d).  We also observed that SjS patients have lower C4 serum levels than controls (p < 1x10-20, Extended 
Data Fig. 7e) even after correcting for C4 gene copy number (p < 1x10-8, Extended Data Fig. 7f), 
suggesting that hypocomplementemia in SjS is not simply due to C4 genetics but also reflects disease 
effects on ambient complement levels, for example due to complement consumption.  The ages of 
pronounced sex difference in complement levels corresponded to the ages at which men and women differ 
in disease incidence: in schizophrenia, men outnumber women among cases incident in early adulthood, 
but not among cases incident after age 402; in SLE, women greatly outnumber men among cases incident 
during the child-bearing years, but not among cases incident after age 50 or during childhood36; in SjS, the 
large relative vulnerability of women declines in magnitude after age 5037.   
 
Our results indicate that the MHC genomic region shapes vulnerability in lupus and SjS – two of the three 
most common rheumatic autoimmune diseases – in a very different way than in type I diabetes, rheumatoid 
arthritis, and celiac disease.  In the latter diseases, precise interactions between specific HLA protein 
variants and specific autoantigens determine risk 13,14.  In SLE and SjS, however, the genetic variation 
implicated here points instead to the continuous, chronic interaction of the immune system with very many 
potential autoantigens.  Because complement facilitates the rapid clearance of debris from dead and injured 
cells, elevated levels of C4 protein likely attenuate interactions between the adaptive immune system and 
ribonuclear self-antigens at sites of cell injury, pre-empting the development of autoimmunity.  The 
additional C4-independent genetic risk effect described here (associated with rs2105898) may also affect 
autoimmunity broadly, rather than antigen-specifically, by regulating expression of many HLA class II 
genes (including DRB1, DQA1, and DQB1).  Mouse models of SLE indicate that once tolerance is broken 
for one self-antigen, autoreactive germinal centers generate B cells targeting other self-antigens38; such 
“epitope spreading” could lead to autoreactivity against many related autoantigens, regardless of which 
antigen(s) are involved in the earliest interactions with immune cells.  Further supporting such a model, 
higher copy number of C4 associates with lower risk of AQP4-IgG-seropositive neuromyelitis optica 
(NMO-IgG+)39, in which seropositive patients have increased incidence of other non-organ-specific 
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autoantibodies such as those seen in SLE and SjS40.  B-cells also express the complement receptors CR1 
and CR241, providing an additional candidate mechanism for regulation by C4 and C3.   
 
We note that the role of complement proteins in preventing the emergence of autoimmunity may be very 
different than their (potentially disease-exacerbating) role once autoimmunity has been established.  Also, 
our genetic findings address the development of SLE and SjS rather than complications that arise in any 
specific organ. A few percent of SLE patients develop neurological complications that can include 
psychosis42; though psychosis is also a symptom of schizophrenia, neurological complications of SLE do 
not resemble schizophrenia more broadly, and likely have a different etiology.   
 
The same C4 alleles that increase vulnerability to schizophrenia appeared to protect strongly against SLE 
and SjS.  This pleiotropy will be important to consider in efforts to engage the complement system 
therapeutically.  The complement system contributed to these pleiotropic effects more strongly in men than 
in women.  Moreover, though the natural allelic series at C4 allowed human-genetic analysis to establish 
dose-risk relationships for C4 in men and women, sexual dimorphism in the complement-protein levels also 
included complement component 3 (C3).  Why and how biology has come to create this sexual dimorphism 
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Figure 1.  Association of SLE and Sjögren’s syndrome (SjS) with C4 alleles   
 
(a) Levels of SLE risk associated with 11 common combinations of C4A and C4B gene copy number.  The 
color of each circle reflects the level of SLE risk (odds ratio) associated with a specific combination 
of C4A and C4B gene copy numbers relative to the most common combination (two copies of C4A 
and two copies of C4B) in gray.  The area of each circle is proportional to the number of individuals 
with that number of C4A and C4B genes.  Paths from left to right on the plot reflect the effect of 
increasing C4A gene copy number (greatly reduced risk); paths from bottom to top reflect the effect of 
increasing C4B gene copy number (modestly reduced risk); and diagonal paths from upper left to lower 
right reflect the effect of exchanging C4B for C4A copies (modestly reduced risk).  Data are from 
analysis of 6,748 SLE cases and 11,516 controls of European ancestry.  The odds ratios are reported 
with confidence intervals in Extended Data Fig. 2c. 
(b) SLE and SjS risk associated with common combinations of C4 structural allele and MHC SNP 
haplotype.  For each C4 locus structure, separate odds ratios are reported for each “haplogroup,” i.e., 
the MHC SNP haplotype background on which the C4 structure segregates.  Data are from analyses 
of 6,748 SLE cases and 11,516 controls for the left plot and 673 SjS cases and 1,153 controls for the 
right plot.  Error bars represent 95% confidence intervals around the effect size estimate for each allele. 
 
Figure 2.  C4 and trans-ancestral analysis of the MHC association signal in SLE 
 
(a) Common C4 alleles exhibit similar strengths of association (odds ratios) in European-ancestry and 
African American (1,494 SLE cases; 5,908 controls) cohorts.  Error bars represent 95% confidence 
intervals around the effect size estimate for each sex. 
(b) Analysis of SLE risk across combinations of C4-B(S) and DRB1*03:01 genotypes in an African 
American SLE case–control cohort, in which the two alleles exhibit very little LD (r2 = 0.10).  On each 
DRB1*03:01 genotype background, additional C4-B(S) alleles increase risk (i.e. within each 
grouping).  Whereas on each C4-B(S) background, DRB1*03:01 alleles have no appreciable 
relationship with risk (this can be seen by comparing, for example, the first of the three points from 
each group).  Error bars represent 95% confidence intervals around the effect size estimate for each 
combination of C4-B(S) and DRB1*03:01. 
 
Figure 3.  Sex differences in the magnitude of C4 genetic effects and complement protein 
concentrations. 
 
(a) SLE risk (odds ratios) associated with the four most common C4 alleles in men (x-axis) and women 
(y-axis) among 6,748 affected and 11,516 unaffected individuals of European ancestry.  For each sex, 
the lowest-risk allele (C4-A(L)-A(L)) is used as a reference (odds ratio of 1.0).  Shading of each point 
reflects the relative level of SLE risk (darker = greater risk) conferred by C4A and C4B copy numbers 
as in Fig. 2b.  Error bars represent 95% confidence intervals around the effect size estimate for each 
sex. 
(b) Schizophrenia risk (odds ratios) associated with the four most common C4 alleles in men (x-axis) and 
women (y-axis) among 28,799 affected and 35,986 unaffected individuals of European ancestry, 
aggregated by the Psychiatric Genomics Consortium43.  For each sex, the lowest-risk allele (C4-B(S)) 
is used as a reference (odds ratio of 1.0).  For visual comparison with a, shading of each allele reflects 
the relative level of SLE risk.  Error bars represent 95% confidence intervals around the effect size 
estimate for each sex. 
(c) Concentrations of C4 protein in cerebrospinal fluid sampled from 340 adult men (blue) and 167 adult 
women (pink) as a function of age with local polynomial regression (LOESS) smoothing.  
Concentrations are normalized to the number of C4 gene copies in an individual’s genome (a strong 
independent source of variance, Extended Data Fig. 7a) and shown on a log10 scale as a LOESS curve.  
Shaded regions represent 95% confidence intervals derived during LOESS. 
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(d) Levels of C3 protein in cerebrospinal fluid from 179 adult men and 125 adult women as a function of 
age.  Concentrations are shown on a log10 scale as a LOESS curve.  Shaded regions represent 95% 





Creation of a C4 reference panel from whole-genome sequence data 
 
We constructed a reference panel for imputation of C4 structural haplotypes using whole-genome 
sequencing data for 1265 individuals from the Genomic Psychiatry Cohort26.  The reference panel included 
individuals of diverse ancestry, including 765 Europeans, 250 African Americans, and 250 people of 
reported Latino ancestry. 
 
We estimated the diploid C4 copy number, and separately the diploid copy number of the contained HERV 
segment, using Genome STRiP44.  Briefly, Genome STRiP carefully calibrates measurements of read depth 
across specific genomic segments of interest by estimating and normalizing away sample-specific technical 
effects such as the effect of GC content on read depth (estimated from the genome-wide data).  To estimate 
C4 copy number, we genotyped the segments 6:31948358–31981050 and 6:31981096–32013904 (hg19) 
for total copy number, but masked the intronic HERV segments that distinguish short (S) from long (L) C4 
gene isotypes.  For the HERV region, we genotyped segments 6:31952461–31958829 and 6:31985199–
31991567 (hg19) for total copy number.  Across the 1,265 individuals, the resultant locus-specific copy-
number estimates exhibited a strongly multi-modal distribution (Extended Data Fig. 1a) from which 
individuals’ total C4 copy numbers could be readily inferred. 
 
We then estimated the ratio of C4A to C4B genes in each individual genome.  To do this, we extracted reads 
mapping to the paralogous sequence variants that distinguish C4A from C4B (hg19 coordinates 
6:31963859–31963876 and 6:31996597–31996614) in each individual, combining reads across the two 
sites.  We included only reads that aligned to one of these segments in its entirety.  We then counted the 
number of reads matching the canonical active site sequences for C4A (CCC TGT CCA GTG TTA GAC) 
and C4B (CTC TCT CCA GTG ATA CAT).  We combined these counts with the likelihood estimates of 
diploid C4 copy number (from Genome STRiP) to determine the maximum likelihood combination of C4A 
and C4B in each individual (Extended Data Fig. 1b).  We estimated the genotype quality of the C4A and 
C4B estimate from the likelihood ratio between the most likely and second most likely combinations. 
 
To phase the C4 haplotypes, we first used the GenerateHaploidCNVGenotypes utility in Genome STRiP 
to estimate haplotype-specific copy-number likelihoods for C4 (total C4 gene copy number), C4A, C4B, 
and HERV using the diploid likelihoods from the prior step as input.  Default parameters for 
GenerateHaploidCNVGenotypes were used, plus -genotypeLikelihoodThreshold 0.0001.  The output was 
then processed by the GenerateCNVHaplotypes utility in Genome STRiP to combine the multiple estimates 
into likelihood estimates for a set of unified structural alleles.  GenerateCNVHaplotypes was run with 
default parameters, plus -defaultLogLikelihood -50, -unknownHaplotypeLikelihood -50, and -
sampleHaplotypePriorLikelihood 2.0.  The resultant VCF was phased using Beagle 4.1 
(beagle_4.1_27Jul16.86a) in two steps: first, performing genotype refinement from the genotype 
likelihoods using the Beagle gtgl= and maxlr=1000000 parameters, and then running Beagle again on the 
output file using gt= to complete the phasing. 
 
Our previous work suggested that several C4 structures segregate on different haplotypes, and probably 
arose by recurrent mutation on different haplotype backgrounds7.  The GenerateCNVHaplotypes utility 
requires as input an enumerated set of structural alleles to assign to the samples in the reference cohort, 
including any structurally equivalent alleles, with distinct labels to mark them as independent, plus a list of 
samples to assign (with high likelihood) to specific labeled input alleles to disambiguate among these 
recurrent alleles.  The selection of the set of structural alleles to be modeled, along with the labeling strategy, 
is important to our methodology and the performance of the reference panel.  In the reference panel, each 
input allele represents a specific copy number structure and optionally includes a label that differentiates 
the allele from other independent alleles with equivalent structure.  We use the notation <H_n_n_n_n_L> 
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to identify each allele, where the four integers following the H are, respectively, the (redundant) haploid 
count of the total number of C4 copies, C4A copies, C4B copies and HERV copies on the haplotype.  For 
example, <H_2_1_1_1> was used to represent the "AL-BS" haplotype.  The optional final label L is used 
to distinguish potentially recurrent haplotypes with otherwise equivalent structures (under the model) that 
should be treated as independent alleles for phasing and imputation. 
 
To build the reference panel, we experimentally evaluated a large number of potential sets of structural 
alleles and methods for assigning labels to potentially recurrent alleles.  For each evaluation, we built a 
reference panel using the 1265 reference samples, and then evaluated the performance of the panel via 
cross-validation, leaving out 10 different samples in each trial (5 samples in the last trial) and imputing the 
missing samples from the remaining samples in the panel.  The imputed results for all 1265 samples were 
then compared to the original diploid copy number estimates to evaluate the performance of each candidate 
reference panel (Extended Data Table 1). 
 
Using this procedure, we selected a final panel for downstream analysis that used a set of 29 structural 
alleles representing 16 distinct allelic structures (as listed in the reference panel VCF file).  Each allele 
contained from one to three copies of C4.  Three allelic structures (AL-BS, AL-BL, and AL-AL) were 
represented as a set of independently labeled alleles with 9, 3, and 4 labels, respectively. 
 
To identify the number of labels to use on the different alleles and the samples to "seed" the alleles, we 
generated "spider plots" of the C4 locus based on initial phasing experiments run without labeled alleles, 
and then clustered the resulting haplotypes in two dimensions based on the Y-coordinate distance between 
the haplotypes on the left and right sides of the spider plot.  Clustering was based on visualizing the clusters 
(Extended Data Fig. 1c) and then manually choosing both the number of clusters (labels) to assign and a 
set of confidently assigned haplotypes to use to "seed" the clusters in GenerateCNVHaplotypes.  This 
procedure was iterated multiple times using cross-validation, as described above, to evaluate the imputation 
performance of each candidate labeling strategy. 
 
Within the data set used to build the reference panel, there is evidence for individuals carrying seven or 
more diploid copies of C4, which implies the existence of (rare) alleles with four or more copies of C4.  In 
our experiments, attempting to add additional haplotypes to model these rare four-copy alleles reduced 
overall imputation performance.  Consequently, we conducted all downstream analyses using a reference 
panel that models only alleles with up to three copies of C4.  In the future, larger reference panels might 
benefit from modeling these rare four-copy alleles. 
 




Genetic data for SLE 
 
For analysis of systemic lupus erythematosus (SLE), collection and genotyping of the European-ancestry 
cohort (6,748 cases, 11,516 controls, genotyped by ImmunoChip) as previously described3.  Collection and 
genotyping of the African-American cohort (1,494 cases, 5,908 controls, genotyped by OmniExpress) as 
previously described5.   
 
Genetic data for SjS 
 
For analysis of Sjögren’s syndrome (SjS), collection and genotyping of the European-ancestry cohort (673 
cases, 1,153 controls, genotyped by Omni2.5) as previously described32 and available in dbGaP under study 
accession number phs000672.v1.p1. 
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Genetic data for schizophrenia 
 
The schizophrenia analysis made use of genotype data from 40 cohorts of European ancestry (28,799 cases, 
35,986 controls) made available by the Psychiatric Genetics Consortium (PGC) as previously described43.  
Genotyping chips used for each cohort are listed in Supplementary Table 3 of that study. 
 
 
Imputation of C4 alleles 
 
The reference haplotypes described above were used to extend the SLE, SjS, or schizophrenia cohort SNP 
genotypes by imputation.  SNP data in VCF format were used as input for Beagle v4.145,46 for imputation 
of C4 as a multi-allelic variant.  Within the Beagle pipeline, the reference panel was first converted to bref 
format.  From the cohort SNP genotypes, we used only those SNPs from the MHC region (chr6:24-34 Mb 
on hg19) that were also in the haplotype reference panel.  We used the conform-gt tool to perform strand-
flipping and filtering of specific SNPs for which strand remained ambiguous.  Beagle was run using default 
parameters with two key exceptions: we used the GRCh37 PLINK recombination map, and we set the 
output to include genotype probability (i.e., GP field in VCF) for correct downstream probabilistic 
estimation of C4A and C4B joint dosages. 
 
 
Imputation of HLA alleles 
 
For HLA allele imputation, sample genotypes were used as input for the R package HIBAG47.  For both 
European ancestry and African American cohorts, publicly available multi-ethnic reference panels 
generated for the most appropriate genotyping chip (i.e. Immunochip for European ancestry SLE cohort, 
Omni 2.5 for European ancestry SjS cohort, and OmniExpress for African American SLE cohort) were 
used48.  Default parameters were used for all settings.  All class I and class II HLA genes were imputed.  




Associating single and joint C4 structural allele dosages to SLE and SjS in European ancestry 
individuals 
 
The analysis described above yields dosage estimates for each of the common C4 structural haplotypes 
(e.g., AL-BS, AL-AL, etc.) for each genome in each cohort.  In addition to performing association analysis 
on these structures (Fig 1b), we also performed association analysis on the dosages of each underlying C4 
gene isotype (i.e. C4A, C4B, C4L, and C4S).  These dosages were computed from the allelic dosage (DS) 
field of the imputation output VCF simply by multiplying the dosage of a C4 structural haplotype by the 
number of copies of each C4 isotype that haplotype contains (e.g., AL-BL contains one C4A gene and one 
C4B gene).   
 
C4 isotype dosages were then tested for disease association by logistic regression, with the inclusion of four 
available ancestry covariates derived from genome-wide principal component analysis (PCA) as additional 
independent variables, PCc,  
 
(1) logit(q) ~ b0 + b1C4 + ScbcPCc + e 
 
where q=E[SLE|X].  For SjS, the model instead included two available multiethnic ancestry covariates from 
dbGaP that correlated strongly with European-specific ancestry covariates (specifically, PC5 and PC7) and 
 17 
smoking status as independent variables.  Coefficients for relative weighting of C4A and C4B dosages were 
obtained from a joint logistic regression, 
 
(2) logit(q) ~ b0 + b1C4A + b2C4B + ScbcPCc + e 
 
The values per individual of b1C4A + b2C4B were used as a combined C4 risk term for estimating both 
association strength (Extended Data Fig. 3a, b) as well as evaluating the relationship between the strength 
of nearby variants’ association with SLE or SjS and linkage with C4 variation (Extended Data Fig. 4a-c). 
 
Joint dosages of C4A and C4B for each individual in the same cohort were estimated by summing across 
their genotype probabilities of paired structural alleles that encode for the same diploid copy numbers of 
both C4A and C4B (Extended Data Fig. 2a, b).  For each individual/genome, this yields a joint dosage 
distribution of C4A and C4B gene copy number, reflecting any possible imputed haplotype-level dosages 
with nonzero probability.  Joint dosages for C4A and C4B diploid copy numbers were tested for association 
with SLE in a joint model with the same ancestry covariates (Fig. 1a), 
 
(3) logit(q) ~ b0 + Si,jbi,jP(C4A=i,C4B=j) + ScbcPCc + e 
 
 
Calculation of composite C4 risk for SLE 
 
Because SLE risk strongly associated with C4A and C4B copy numbers (Fig. 1a) in a manner that can be 
approximated as – but is not necessarily linear or independent – a composite C4 risk score was derived by 
taking the weighted sum of joint C4A and C4B dosages multiplied by the corresponding effect sizes from 
the aforementioned model of the joint C4A and C4B diploid copy numbers.  The weights for calculating 
this composite C4 risk term were computed from the data from the European ancestry cohort, and then 
applied unchanged to analysis of the African American cohort. 
 
 
Associations of variants across the MHC region to SLE and SjS 
 
Genotypes for non-array SNPs were imputed with IMPUTE2 using the 1000 Genomes reference panel; 
separate analyses were performed for the European-ancestry and African American cohorts.  Unless 
otherwise stated, all subsequent SLE analyses were performed identically for both European ancestry and 
African American cohorts.  Dosage of each variant, vi, was tested for association with SLE or SjS in a 
logistic regression including available ancestry covariates (and smoking status for SjS) first alone 
(Extended Data Fig. 3a, b),  
 
(4) logit(q) ~ b0 + b1vi + ScbcPCc + e 
 
then with C4 composite risk (Extended Data Fig. 3c),  
 
(5) logit(q) ~ b0 + b1vi + b2C4 + ScbcPCc + e 
 
where q=E[SLE|X].  For SjS, the simpler weighted (2.3)C4A+C4B model was used instead of composite 
risk term, as the cohort’s size gave poor precision to estimates of risk for many joint (C4A, C4B) copy 
numbers (Extended Data Fig. 3d).  The Pearson correlation between the C4 composite risk term and each 
other variant was computed and squared (r2) to yield a measure of linkage disequilibrium between C4 




Association analyses for specific C4 structural alleles 
 
The C4 structural haplotypes were tested for association with disease (Fig. 1b, 2a) in a joint logistic 
regression that included (i) terms for dosages of the five most common C4 structural haplotypes (AL-BS, 
AL-BL, AL-AL, BS, and AL), (ii) (for SLE and SjS) rs2105898 genotype, and (iii) ancestry covariates and 
(for SjS) smoking status, 
 
(6) logit(q) ~ b0 + b1BS + b2AL + b3ALBS + b4ALBL + b5ALAL + b6 rs2105898+ ScbcPCc + e 
 
where q=E[SLE|X].  Several of these common C4 structural alleles arose multiple times on distinct 
haplotypes; we term the set of haplotypes in which such a common allele appeared as “haplogroups”.  The 
haplogroups can be further tested in a logistic regression model in which the structural allele appearing in 
all member haplotypes is instead encoded as dosages for each of the SNP haplotypes in which it appears.  
These association analyses (Fig. 1b, 2a) were performed as in (6), with structural allele dosages for ALBS, 
ALBL, and ALAL replaced by multiple terms for each distinct haplotype. 
 
To delineate the relationship between C4-BS and DRB1*03:01 alleles – which are highly linked in 
European ancestry haplotypes – allelic dosages per individual in the African American SLE cohort were 
rounded to yield the most likely integer dosage for each.  Although genotype dosages for each are reported 
by BEAGLE and HIBAG respectively, probabilities per haplotype are not linked and multiplying possible 
diploid dosages could yield incorrect non-zero joint dosages.  Joint genotypes were tested as individual 
terms in a logistic regression model (Fig. 2b),  
 
(7) logit(q) ~ b0 + Si,jbi,jP(C4-BS=i,DRB1*03:01=j) + ScbcPCc + e 
 
 
Sex-stratified associations of C4 structural alleles and other variants with SLE, SjS, and 
schizophrenia 
 
Determination of an effect from sex on the contribution of overall C4 variation to risk for each disorder was 
done by including an interaction term between sex and C4; ie. (2.3)C4A+C4B for SLE and SjS and 
estimated C4A expression for schizophrenia: 
 
(8) logit(q) ~ b0 + b2C4 + b3ISex + b4ISexC4 + ScbcPCc + e 
 
Each variant in the MHC region was tested for association with among European ancestry cases and cohorts 
in a logistic regression as in models (4)–(6) using only male cases and controls, and then separately using 
only female cases and controls (Extended Data Fig. 6a-c).  Likewise, allelic series analyses were 
performed as in (7), but in separate models for men and women (Fig. 3a, b). 
 
To assess the relationship between sex bias in the risk associated with a variant and linkage to C4 composite 
risk (as non-negative r2), male and female log-odds were multiplied by the sign of the Pearson correlation 
between that variant and C4 composite risk before taking the difference. 
 
 
Analyses of cerebrospinal fluid  
 
Cerebrospinal fluid (CSF) from healthy individuals was obtained from two research panels.  The first panel, 
consisting of 533 donors (327 male, 126 female) from hospitals around Utrecht, Netherlands, was described 
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previously49,50.  The donors were generally healthy research participants undergoing spinal anesthesia for 
minor elective surgery.  The same donors were previously genotyped using the Illumina Omni SNP array.  
To estimate C4 copy numbers, we used SNPs from the MHC region (chr6:24-34 Mb on hg19) as input for 
C4 allele imputation with Beagle, as described above in Imputation of C4 alleles.   
 
The second CSF panel sampled specimens from 56 donors (14 male, 42 female) from Brigham and 
Women’s Hospital (BWH; Boston, MA, USA) under a protocol approved by the institutional review 
board at BWH (IRB protocol ID no. 1999P010911) with informed consent.  These samples were 
originally obtained to exclude the possibility of infection, and clinical analyses had revealed no evidence 
of infection.  Donors ranged in age from 18 to 64 years old.  Blood samples from the same individuals 
were used for extraction of genomic DNA, and C4 gene copy number was measured by droplet digital 
PCR (ddPCR) as previously described7.  Samples were excluded from measurements if they lacked C4 
genotypes, sex information, or contained visible blood contamination. 
 
C4 measurements were performed by sandwich ELISA of 1:400 dilutions of the original CSF sample using 
goat anti-sera against human C4 as the capture antibody (Quidel, A305, used at 1:1000 dilution), FITC-
conjugated polyclonal rabbit anti-human C4c as the detection antibody (Dako, F016902-2, used at 1:3000 
dilution), and alkaline phosphatase–conjugated polyclonal goat anti-rabbit IgG as the secondary antibody 
(Abcam, ab97048, used at 1:5000 dilution).  C3 measurements were performed using the human 
complement C3 ELISA kit (Abcam, ab108823).   
 
Because C4 gene copy number had a large and proportional effect on C4 protein concentration in these CSF 
samples (Extended Data Fig. 7a), we corrected for C4 gene copy number in our analysis of relationship 
between sex and C4 protein concentration, by normalizing the ratio of C4 protein (in CSF) to C4 gene 
copies (in genome).  Therefore, these analyses included only samples for which DNA was available or C4 
was successfully imputed.  In total, 495 (332 male, 163 female) C4 and 304 (179 male, 125 female) C3 
concentrations were obtained across both cohorts.  Log-concentrations of C3 (ng/mL) and C4 (ng/[mL, per 
C4 gene copy number]) protein were then used separately in linear regression models to estimate a sex-
unbiased cohort-specific offset for each protein, 
 
(9) log10(C3 or C4 concentration) ~ b0 + b1Imale + b2Icohort + e 
 
to be applied to all concentrations for that protein.  Estimation of average measurements by age for each 
sex was done by local polynomial regression smoothing (LOESS) (Fig. 3c, d).  To evaluate the significance 
of sex effects, we used these cohort-corrected concentrations estimates and analyzed them with the non-
parametric unsigned Mann-Whitney rank–sum test comparing concentration distributions for males and 
females.   
 
Analyses of blood plasma  
 
Blood plasma was collected and immunoturbidimetric measurements of C3 and C4 protein in 1,844 
individuals (182 men, 1662 women) by Sjögren's International Collaborative Clinical Alliance (SICCA) 
from individuals with and without SjS as previously described51.  C4 copy numbers for these individuals 
were previously imputed for use in logistic regression of SjS risk.  As C4 copy number has an effect on 
measured C4 protein similar to CSF (Extended Data Fig. 7b), we normalized C4 levels to them in all 
following analyses.  Estimation of average measurements by age for each sex was done by local polynomial 
regression smoothing (LOESS) on log-concentrations of C3 (mg/dL) and C4 (mg/[dL, per C4 gene copy 
number]) protein (Extended Data Fig. 7c, d).  To evaluate the significance of sex bias within age ranges 
displaying the greatest difference (informed by LOESS), we analyzed individuals in these bins with the 
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non-parametric unsigned Mann-Whitney rank–sum test comparing concentration distributions for males 
and females.  
 
Difference in C4 protein levels between individual with and without SjS was done by performing a non-
parametric unsigned Mann-Whitney rank–sum test on C4 protein levels with and without normalization to 
C4 genomic copy number (Extended Data Fig. 7e, f). 
 
Data Availability Statement 
 
Individual genotype data for Sjögren's syndrome cases and controls and individual plasma concentrations 
for C4 and C3 are available in dbGaP under accession number phs000672.v1.p1.  Individual genotype 
data for schizophrenia cases and controls are available by application to the Psychiatric Genomics 
Consortium (PGC).  Questions regarding individual genotype data for SLE cases and controls of 
European and/or African American ancestry can be directed to Timothy J. Vyse 
(timothy.vyse@kcl.ac.uk).  Data resources (reference haplotypes), software scripts and instructions for 
imputing C4 alleles into SNP data sets are available on the McCarroll lab web site at 
http://mccarrolllab.org/resources/resources-for-c4/.  Genotype and protein concentration data for CSF 
samples are available upon request.  
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Extended Data Figure 1.  A panel of 2,530 reference haplotypes (created from whole-genome 
sequence data) containing C4 alleles and SNPs across the MHC genomic region enables imputation 
of C4 alleles into large-scale SNP data.   
 
(a) Distributions (across 1,265 individuals) of total C4 gene copy number (C4A + C4B), as measured from 
read depth of coverage across the C4 locus, in whole-genome sequencing data. 
(b) The relative numbers of reads that overlap sequences specific to C4A or C4B (together with the total 
C4 gene copy number as in a) are used to infer the underlying copy numbers of the C4A and C4B 
genes.  For example, in an individual with four C4 genes, the presence of equal numbers of reads 
specific to C4A or C4B suggests the presence of two copies each of C4A and C4B.  Precise statistical 
approaches (including inference of probabilistic dosages), and further approaches for phasing C4 
allelic states with nearby SNPs to create reference haplotypes, are described in Methods. 
(c) The SNP haplotypes flanking each C4 allele are shown as rows (SNPs as columns), with white and 
black representing the major and minor allele of each SNP.  Gray lines at the bottom indicate the 
physical location of each SNP along chromosome 6.  The differences among the haplotypes are most 
pronounced closest to C4 (toward the center of the plot), as historical recombination events in the 
flanking megabases will have caused the haplotypes to be less consistently distinct at greater genomic 
distances from C4.  The patterns indicate that many combinations of C4A and C4B gene copy numbers 
have arisen recurrently on more than one SNP haplotype, a relationship that can be used in association 
analyses (Fig. 1b). 
 
Extended Data Figure 2.  Aggregation of joint C4A and C4B genotype probabilities per individual 
across imputed C4 structural alleles for estimation of SLE risk for each combination. 
 
(a) An individual’s joint C4A and C4B gene copy number can be calculated by summing the C4A and C4B 
gene contents for each possible pair of two inherited alleles.  Many pairings of possible inherited alleles 
result in the same joint C4A and C4B gene copy number.   
(b) Each individual’s C4A and C4B gene copy number was imputed from their SNP data, using the 
reference haplotypes summarized in Extended Data Fig. 1c.  For >95% of individuals (exemplified by 
samples 1–6 in the figure), this inference can be made with >90% certainty/confidence (the areas of the 
circles represent the posterior probability distribution over possible C4A/C4B gene copy numbers).  For 
the remaining individuals (exemplified by samples 7–9 in the figure), greater statistical uncertainty 
persists about C4 genotype.  To account for this uncertainty, in downstream association analysis, all C4 
genotype assignments are handled as probabilistic gene dosages – analogous to the genotype dosages 
that are routinely used in large-scale genetic association studies that use imputation. 
(c) Odds ratios and 95% confidence intervals underlying each of the C4-genotype risk estimates in Fig. 1a 
presented as a series of panels for each observed copy number of C4B, with increasing copy number of 
C4A for that C4B dosage (x-axis).  Data are from analysis of 6,748 SLE cases and 11,516 controls of 
European ancestry. 
 
Extended Data Figure 3.  Conditional association analyses for genetic markers across the extended 
MHC genomic region within the European-ancestry SLE and Sjögren’s syndrome (SjS) cohort.   
 
(a) Association of SLE with genetic markers (SNPs and imputed HLA alleles) across the extended MHC 
locus within the European-ancestry SLE cohort (6,748 cases and 11,516 controls).  Orange diamond: 
an initial estimate of C4-related genetic risk, calculated as a weighted sum of the number of C4A and 
C4B gene copies: (2.3)C4A+C4B, with the weights derived from the relative coefficients estimated 
from logistic regression of SLE risk vs. C4A and C4B gene dosages.  This risk score is imputed with 
an accuracy (r2) of 0.77.  Points representing all other genetic variants in the MHC locus are shaded 
orange according to their level of linkage disequilibrium–based correlation to this C4-derived risk 
score. 
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(b) As in a, but for a European-ancestry Sjögren’s syndrome (SjS) cohort (673 cases and 1,153 controls).  
The orange diamond here also represents (2.3)C4A+C4B, with this weighting derived from the relative 
coefficients estimated from logistic regression of SjS  risk vs. C4A and C4B gene dosages 
(c) Association of SLE with genetic markers (SNPs and imputed HLA alleles) across the extended MHC 
locus within the European-ancestry SLE cohort controlling for C4 composite risk (weighted sum of 
risk associated with various combinations of C4A and C4B).  Variants are shaded in purple by their LD 
with rs2105898, an independent association identified from trans-ancestral analyses. 
(d) As in c, but in association with a European-ancestry SjS cohort.  Here a simpler linear model of risk 
contributed by C4A and C4B was used instead of a weighted sum across all possible combinations.  
 
Extended Data Figure 4.  Using C4 gene variation to understand the appearance of trans-ancestral 
disparity in MHC association signals, and to fine-map an additional genetic effect 
 
All panels show association signals (for SLE and SjS) for variants in a multi-megabase region of human 
chromosome 6 containing the MHC region including the HLA and C4 genes. 
(a) Relationship between SLE association [-log10(p), y-axis] and LD to the weighted C4 risk score (x-axis) 
for genetic markers and imputed HLA alleles across the extended MHC locus.  In this European-
ancestry cohort, it is unclear (from this analysis alone) whether the association with the markers in the 
predominant ray of points (at a ~45° angle from the x-axis) is driven by variation at C4 or by the long 
haplotype containing DRB1*03:01 (green), DQA1*05:01 (blue), and B*08:01 (red).  In addition, at 
least one independent association signal (a ray of points at a higher angle in the plot, with strong 
association signals and only weak LD-based correlation to C4 and DRB1*0301) with some LD to 
DRB1*15:01 (maroon) is also present. 
(b) Analysis as in a, but for associations to SjS in a cohort of European ancestry.  As in SLE, it is initially 
unclear whether the genetic association signal is driven by variation at C4 or by linked HLA alleles, 
DRB1*03:01 (green), DQA1*05:01 (blue), and B*08:01 (red).  There is also an independent 
association signal with LD to DRB1*15:01 (maroon).   
(c) Analysis as in a, but of an African American SLE case–control cohort (in which LD in the MHC region 
is more limited).  Many MHC-region SNPs associate with SLE in proportion to their LD with the 
weighted C4 risk score inferred from the earlier analysis of the European-ancestry cohort; this C4-
derived risk score itself associates with SLE at p = 4.3x10-19 in a logistic regression on 1,494 SLE 
cases and 5,908 controls.  No similarly strong association is observed for DRB1*03:01, DQA1*05:01, 
or B*08:01, HLA alleles which are in strong LD with C4 risk on European-ancestry (but not African 
American) haplotypes.  An independent association signal is also present in this cohort, more clearly 
in LD with the DRB1*15:03 allele (maroon). 
(d) LD in the European-ancestry SLE cohort between the composite C4 risk term (weighted sum of risk 
associated with various combinations of C4A and C4B from Fig. 2a) and variants in the MHC region 
as r2 (y-axis).   
(e) As in d, but for the African American SLE cohort. 
(f) LD (to C4 composite risk) for the same variants in European-ancestry individuals (x-axis) and African 
Americans (y-axis).  Note the abundance of variants that have greater LD with C4 risk among 
European-ancestry individuals than among African Americans.  Also, several groups of variants have 
equivalent LD (to C4 risk) in European ancestry individuals but exhibit a range of LD to C4 risk among 
African Americans.   
(g) Associations with SLE (-log10 p-values) for the same variants in European ancestry (x-axis) and 
African American (y-axis) case-control cohorts.  Orange shading represents the extent of LD with C4 
risk in European ancestry individuals.  Variants with strong European-specific association to SLE are 
generally in strong LD with C4 risk among Europeans-ancestry individuals. 
(h) Comparison of the inferred effect size from association of genetic markers with SLE (unconditioned 
log-odds ratios) among European-ancestry (x-axis) and African American (y-axis) research 
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participants.  As also seen in g, variants with discordant associations to SLE (across populations) tend 
also to be in strong LD to C4 risk among European-ancestry individuals. 
(i) As in g, but now controlling for the effect of C4 variation in analysis of the European-ancestry cohort 
(x-axis).  Note that controlling for C4 risk in European-ancestry individuals alone greatly aligns 
(relative to g) the patterns of association between European ancestry and African American cohorts. 
(j) As in i, but now also controlling for the effect of C4 in associations of the African American cohort.  
Note that due to the lack of strong LD relationships between C4 and variants in the MHC region in 
African Americans (e), this further adjustment does not change results strongly (relative to i).  The 
independent signal, rs2105898, and HLA alleles, DRB1*15:01 and DRB1*15:03, are also highlighted.  
LD with rs2105898 in European-ancestry individuals is indicated by purple shading. 
(k) Comparison of the inferred effect sizes from association of genetic markers with SLE (log-odds ratios) 
controlling for C4-derived risk among European-ancestry (x-axis) and African American (y-axis) 
research participants.  Two SNPs (rs2105898 and rs9271513) that form a short haplotype common to 
both ancestry groups are among the strongest associations in both cohorts.  (Their association to SLE 
in the European-ancestry cohort was initially much less remarkable than that of other SNPs that are in 
strong LD with C4.)  LD with rs2105898 in European-ancestry individuals is indicated by purple 
shading. 
(l) As in i, but with variants shaded by whether they exhibit greater LD to rs2105898 in Europeans (blue) 
or African Americans (red).   
 
Extended Data Figure 5.  Relationship of rs2105898 alleles to a known ZNF143 binding motif in the 
XL9 region of the MHC class II locus 
 
(a) Location of rs2105898 (yellow line at center) within the XL9 region, with relevant tracks showing 
overlapping histone marks and transcription factor binding peaks (from ENCODE52), visualized with 
the UCSC genome browser53.   
(b) ZNF143 consensus binding motif as a sequence logo, with the letters colored if the base is present in 
>5% of observed instances.  The alleles of rs2105898 are indicated by outlined box surrounding the 
base. 
 
Extended Data Figure 6.  Relationships between sex bias of disease associations and LD to C4 risk 
for variants in the MHC region. 
 
(e) Relationship between male bias in SLE risk (difference between male and female log–odds ratios) and 
LD with C4 risk for common (minor allele frequency [MAF] > 0.1) genetic markers across the extended 
MHC region.  For each SNP, the allele for which sex risk bias is plotted is the allele that is positively 
correlated (via LD) with C4-derived risk score. 
(f) Relationship between male bias in SjS risk (log-odds ratios) and LD with C4 risk for common (minor 
allele frequency [MAF] > 0.1) genetic markers across the extended MHC region.  For each SNP, the 
allele for which sex risk bias is plotted is the allele that is positively correlated (via LD) with C4-derived 
risk score. 
(g) Relationship of male bias in schizophrenia risk (log–odds ratios) and LD to C4A expression for 
common (MAF > 0.1) genetic markers across the extended MHC region.  For each SNP, the allele for 
which sex risk bias is plotted is the allele that is positively correlated (via LD) with imputed C4A 
expression, as previously described7. 
 
Extended Data Figure 7.  Correlation of C4 protein measurements in cerebrospinal fluid and blood 




(a) Measurements of C4 protein in CSF obtained by ELISA are presented as log10(ng/mL) (y-axis) for each 
observed or imputed copy number of total C4 (x-axis, here showing most likely copy number from 
imputation).  Because C4 gene copy number affects C4 protein levels so strongly, we normalized C4 
protein measurements to each donor’s C4 gene copy number in subsequent analyses (Fig. 3c).  Bars 
indicate median values for each C4 copy number. 
(b) Measurements of C4 protein in blood plasma obtained by immunoturbidimetric assays are presented as 
log10(mg/dL) (y-axis) for each imputed most-likely copy number of C4 genes (x-axis).  Because C4 
gene copy number affects C4 protein levels so strongly, we normalized C4 protein measurements by 
C4 gene copy number in subsequent analyses as in c.  Due to the number of observations (n = 1,844 
total), the plot is downsampled to 500 points; the median bars shown are for all individuals (before 
downsampling). 
(c) Levels of C4 protein in blood plasma from 182 adult men and 1662 adult women as a function of age.  
Concentrations are normalized to the number of C4 gene copies in an individual’s genome (a strong 
independent source of variance) and shown on a log10 scale as a LOESS curve.  Shaded regions 
represent 95% confidence intervals derived during LOESS. 
(d) Levels of C3 protein in blood plasma as a function of age from the same individuals in panel c.  
Concentrations are shown on a log10 scale as a LOESS curve.  Shaded regions represent 95% confidence 
intervals derived during LOESS. 
(e) C4 protein in blood plasma was measured in 670 individuals with SjS (red) and 1,151 individuals 
without SjS (black) and is shown on a log10 scale (x-axis).  Vertical stripes represent median levels for 
cases and controls separately.  Comparison of the two sets was done with a non-parametric two-sided 
Mann-Whitney rank–sum test (p = 4.8x10-21). 
(f) As in e, but concentrations are normalized to the number of C4 gene copies in an individual’s genome 
and this per-copy amount is shown on a log10 scale (x-axis).  Comparison of the two sets was done with 
a non-parametric two-sided Mann-Whitney rank–sum test (p = 7.6x10-9). 
 
Extended Data Table 1.  Imputation accuracy for C4 copy numbers in European ancestry and 
African American haplotypes. 
 
Imputation accuracy was evaluated by correlation of imputation results to C4 gene copy numbers directly 
inferred from WGS data.  Aggregated copy numbers imputed from each round of leaving 10 individuals 
out were correlated with the directly-typed measurements and are reported as r2 for each feature of C4 
structural variation for European ancestry and African American members of the reference panel separately.   
 
Extended Data Table 2.  Frequency of common C4 alleles and their LD-based correlation with HLA 
alleles in European ancestry and African American cohorts. 
 
For each common C4 allele and HLA gene, the allele with strongest LD (r2) is listed if present on more than 
half of the haplotypes with that C4 allele (exact fraction in %).  r2 values greater than 0.4 are highlighted to 
point out particularly strong C4-HLA allele correlations, such as for several HLA alleles with the C4-B(S) 
allele in European ancestry individuals.  Some common C4 alleles are further subdivided into distinct 
haplotypes used in imputation (and in Fig. 1b), as defined by shared alleles from variants flanking C4.  Note 
that some alleles such as C4-A(L)-A(L)-3 are present at a low frequency in African Americans that might 
reflect their presence on admixed European-origin haplotypes spanning this region, whereas others such as 
C4-B(S) are likely to also exist on African haplotypes – these differences between C4 alleles are also 
reflected in the similarity of LD with HLA alleles to the corresponding row of the European ancestry section. 
 
Extended Data Table 3.  Results of association analyses of SLE risk against C4 variation, HLA alleles, 
and/or rs2105898 in European ancestry and African American cohorts. 
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Coefficients (beta, standard error) and p-values (as -log10(p)) for individual terms composing several 
relevant logistic regression models for predicting SLE risk in a European ancestry cohort of 6,748 SLE 
cases and 11,516 controls and an African American cohort of 1,494 SLE cases and 5,908 controls.  Each 
analysis also included ancestry-specific covariates.  For each model, the Akaike information criterion (AIC) 
and overall p-value (as determined by Chi-squared likelihood-ratio test) are given at the right to indicate 
the relative strengths of similar models for each ancestry cohort. 
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